Our Science: First, Faster, and for Patients

At AbbVie, our R&D teams are chasing bold goals. The therapies and solutions that no one else has achieved or even attempted. And we want to be there first. That's what we go after every day for our patients.

tom hudson video thumbnail
A Conversation with Tom Hudson

AbbVie’s Chief Scientific Officer

A Conversation with Tom Hudson

AbbVie’s Chief Scientific Officer


I’m proud every day because we try to do the things that no one else is attempting or has succeeded in. We want to be there first.

Tom Hudson, M.D.
SVP, Chief Scientific Officer, Global Research

Our research & development approach

Science and innovation are the lifeblood of our company. From drug discovery to clinical trials to regulatory approval, we're pursuing new ways to address patients' most challenging health issues.

Since our launch in 2013, we've invested more than $55 billion in R&D. This enables us to discover and deliver innovative medicines and products that solve serious health issues, enhance people's lives today, and address tomorrow's medical challenges.

We focus on core areas where our proven expertise and bold thinking have the greatest potential to solve unmet needs. These areas are oncology, immunology, neuroscience, eye care, medical aesthetics and other specialty areas.


People

To develop innovative medicines, you need innovative people. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.

Pipeline

Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver medicines and solutions for patients.

Performance

The need to do more for patients motivates our R&D work. By investing in boundary-pushing approaches, we aim to advance programs with a stronger probability of success and move assets forward faster.

AbbVie’s research pipeline

At a glance: Pipeline highlights

Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver new medicines and solutions for patients. Our pipeline includes ~75 programs in mid- and late-stage development and ~60 programs in early-stage development.

Progress
~50
new molecular entities
Programs
75
+
clinical programs
impact
75
+
conditions treated
investment
$7.1
b
R&D investment in 2022

A community of global thinkers

To develop innovative medicines, you need innovative people — lots of them. We have robust teams of biologists, chemists, clinicians, mathematicians, data scientists, engineers, and others working side by side with colleagues in regulatory affairs, patient safety, manufacturing and more. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.

Get Involved

Interested in joining our team of innovative scientists and researchers?